The trial of the insulin-like growth factor-1 receptor (IGF-1R) inhibitor figitumumab in combination with carbo/taxol as first line therapy for advanced NSCLC was officially closed after it was determined that the experimental arm would not have a meaningful chance of appearing su

When one reviews the excitement that has been generated over the last several years in regards to the advancement of therapy for NSCLC, it becomes painfully apparent that patients with adenocarcinoma have reaped the greatest benefits, and patients with squamous cell lung cancer have been more or less left out in the cold. The addition of Avastin to doublet chemotherapy prolongs life for patients with non-squamous cell lung cancer, while patients with squamous cell lung cancers have an increased risk of life-threatening bleeding from the lungs.